Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $654K | — | — | — |
| Operating income | -$60.5M | -$68.5M | -$106M | -$109M |
| Operating margin | -9252.1% | — | — | — |
| Net income | -$59.3M | -$66.4M | -$98.3M | -$100.0M |
| Net margin | -9063.8% | — | — | — |
| EPS (diluted) | -$36.36 | -$12.40 | -$3.09 | -$1.86 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$54.6M | -$59.5M | -$81.2M | -$98.6M |
| Capital expenditures | $672K | $115K | $481K | $397K |
| Free cash flow | -$55.2M | -$59.6M | -$81.6M | -$99.0M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $77.3M | $121M | $35.0M | $63.0M |
| Total assets | $97.1M | $140M | $147M | $269M |
| Total liabilities | $25.0M | $26.3M | $30.1M | $22.0M |
| Shareholders' equity | -$113M | $114M | $117M | $247M |
| Retained earnings | -$115M | -$182M | -$280M | -$380M |
| Shares (wtd avg diluted) | 1.63M | 5.35M | 31.8M | 53.6M |
Every figure is extracted from Lexeo Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.